Eisai (TSE:4523) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

4523 Overzicht aandelen

Eisai Co., Ltd. houdt zich bezig met onderzoek en ontwikkeling, productie, verkoop en import en export van farmaceutische producten in Japan.

Over het bedrijf

4523 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	3/6

Beloningen

Verhandeld tegen 52.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 16.16% per jaar groeien

Risicoanalyse

Het dividend van 2.96% wordt niet goed gedekt door de winst of de vrije kasstromen

Grote eenmalige posten die de financiële resultaten beïnvloeden

Winstmarges (4.4%) zijn lager dan vorig jaar (6.5%)

Eisai Co., Ltd. Concurrenten

Kyowa Kirin

TSE:4151

JP¥1.4t

Shionogi

TSE:4507

JP¥1.8t

Astellas Pharma

TSE:4503

JP¥3.0t

Ono Pharmaceutical

TSE:4528

JP¥916.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Eisai
Historische aandelenkoersen
Huidige aandelenkoers	JP¥5,546.00
52 Week Hoogtepunt	JP¥8,461.00
52 Week Laag	JP¥4,986.00
Bèta	-0.078
11 maand verandering	-8.59%
3 maanden verandering	-14.39%
1 Jaar Verandering	-32.03%
33 jaar verandering	-30.97%
5 jaar verandering	4.72%
Verandering sinds IPO	240.54%

Recent nieuws en updates

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Sep 20

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Sep 05

Recent updates

Rendement voor aandeelhouders

	4523	JP Pharmaceuticals	JP Markt
7D	-0.2%	-1.3%	1.1%
1Y	-32.0%	12.5%	16.6%

Rendement versus industrie: 4523 presteerde slechter dan de JP Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.8 % opleverde.

Rendement versus markt: 4523 presteerde slechter dan JP Market, dat het afgelopen jaar een rendement van 12.8 % opleverde.

Prijsvolatiliteit

Is 4523's price volatile compared to industry and market?
4523 volatility
4523 Average Weekly Movement	6.4%
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	6.5%
10% most volatile stocks in JP Market	10.5%
10% least volatile stocks in JP Market	3.5%

Stabiele aandelenkoers: 4523 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 4523 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1941	11,067	Haruo Naito	www.eisai.co.jp

Eisai Co., Ltd. houdt zich bezig met onderzoek en ontwikkeling, productie, verkoop, import en export van farmaceutische producten in Japan. Het biedt Dayvigo aan, voor de behandeling van slapeloosheid; Lenvima, een antikankermiddel/moleculair gericht geneesmiddel voor de behandeling van schildklierkanker, niercelcarcinoom in combinatie met everolimus, en hepatocellulair carcinoom; Methycobal voor de behandeling van perifere neuropathie; en Halaven, een antikankermiddel voor de behandeling van borstkanker. Het bedrijf levert ook Jyseleca, een januskinaseremmer; Elental, een aminozuurpreparaat met vertakte keten; Goofice en Movicol voor chronische constipatie; Fycompa, een anti-epilepticum; Pariet, een protonpompremmer; Aricept, voor de ziekte van Alzheimer/Dementie met Lewy-lichaampjes; en Chocola BB plus voor het preparaat vitamine B2.

Eisai Co., Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Eisai zich tot de beurswaarde?
4523 fundamentele statistieken
Marktkapitalisatie	JP¥1.54t
Inkomsten(TTM)	JP¥32.65b
Inkomsten(TTM)	JP¥733.85b

47.9x

Koers/Winstverhouding

2.1x

P/S-verhouding

Is 4523 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
4523 resultatenrekening (TTM)
Inkomsten	JP¥733.85b
Kosten van inkomsten	JP¥151.17b
Brutowinst	JP¥582.68b
Overige uitgaven	JP¥550.03b
Inkomsten	JP¥32.65b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 30, 2024

Winst per aandeel (EPS)	115.75
Brutomarge	79.40%
Nettowinstmarge	4.45%
Schuld/Eigen Vermogen Verhouding	19.8%

Hoe presteerde 4523 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.9%

Huidig dividendrendement

141%

Uitbetalingsratio

4523 Overzicht aandelen

Beloningen

Risicoanalyse

Eisai Co., Ltd. Concurrenten

TSE:4151

JP¥1.4t

TSE:4507

JP¥1.8t

TSE:4503

JP¥3.0t

TSE:4528

JP¥916.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Recent updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody